Topic: Amgen Inc.
(Reuters) - Amgen Inc, aiming to secure future sales of its flagship anemia drug Epogen as potential competition emerges, has reached new supply contracts with the two largest operators of U.S. kidney dialysis clinics.The biotechnology company said in a regulatory filing on ...
(Reuters) - Amgen Inc reached a seven-year contract to supply DaVita Inc with nearly all of the anemia drugs needed by the dialysis clinic operator, locking up nearly a third of the U.S. market for its flagship drug Epogen.Amgen said in a ...
LOS ANGELES (Reuters) - The Medicare federal health insurance program has confirmed plans to remove a requirement that kidney dialysis providers keep patient hemoglobin levels above a set minimum -- a move likely to reduce use of Epogen, the anemia drug sold ...
LOS ANGELES (Reuters) - The Medicare federal health insurance program has proposed removing its requirement that kidney dialysis providers keep patient hemoglobin levels above a set minimum, which could lead to lower use of Epogen, the anemia drug sold by Amgen.The government ...
LOS ANGELES (Reuters) - Medicare officials do not plan at this time to change payment terms for anemia drugs used in kidney patients who are undergoing dialysis.The agency, which is slated to issue a final decision on the matter in June, also ...
AMGN) today announced the publication of results from the first open-label study to compare Nplate (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). Data also showed that patients receiving SOC therapies required splenectomies ...
WASHINGTON (Reuters) - U.S. health officials want advisers' input on the risks of anemia drugs made by Amgen Inc and Johnson & Johnson in certain chronic kidney disease patients, including how to adjust dosing and possible label changes.Food and Drug Administration staff, ...
Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely visible. The potential serious adverse events resulting ...
The U.S. Food and Drug Administration and Amgen have notified health care professionals that certain lots of epoetin alfa (Epogen and Procrit) are being recalled, as product vials may contain extremely thin glass flakes (lamellae) that could result in serious adverse events.. ...
Amgen recalls some lots of anemia treatments Epogen and Procrit due to glass flakesABOUT THE RECALL: Some lots of the blockbuster anemia treatments Epogen and Procrit were recalled because the injected drugs may contain glass flakes. Those could cause blood clots, swelling ...
Photo Gallery
-
CYCLING: 2009 Amgen Tour of California Feb 20
Levi Leipheimer during Stage 6 of the 2009 Amgen Tour of California ...ZUMA Press Inc - -
Sacramento California News - February 12, 2009
Lance Armstrong, said that he was happy to be back cycling during ...ZUMA Press Inc - -
Sacramento California News - January 21, 2009
Lori Adams (cq) , 26, of Woodland is unaware as Garmin Slipstream team ...ZUMA Press Inc -
From Around the Web
Video Gallery
-
Amgen Inc. Bests Earnings for Q2
Amgen Inc. (NASDAQ:AMGN)reported Q2 EPS of $1.37 ...2011-07-29 -
Amgen Sees Fractional Gains After Failure ...
Amgen Inc. (AMGN) opened higher and is holding fractional gain ...2011-03-30 -
News Update: EC Approves Amgen, Inc ...
Amgen, Inc. (NASDAQ:AMGN) said Friday that marketing for its ...2010-05-28
